Actively Recruiting
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Led by Han weidong · Updated on 2026-01-22
250
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
CONDITIONS
Official Title
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological confirmation of relapsed or refractory malignancies including Non-Hodgkin lymphoma, Hodgkin lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer, lung cancer, renal-cell cancer, pancreatic cancer, or bile duct cancer
- Age between 12 and 75 years
- ECOG performance status less than 2
- Life expectancy of at least 3 months
- At least one measurable lesion larger than 1 cm by lymphoma or solid tumor criteria
- Received at least two prior chemotherapy regimens and off therapy for at least 4 weeks before Day 1
- Autologous hematopoietic stem-cell transplantation allowed if more than 3 months prior
- Adequate bone marrow, liver, kidney, lung, and heart function as defined by specific blood counts and laboratory values
You will not qualify if you...
- Any autoimmune disease or history of syndromes requiring corticosteroids or immunosuppressive medications
- Serious uncontrolled medical disorders or active infections, especially pulmonary or intestinal
- Active alimentary tract hemorrhage or history of such bleeding within 1 month
- Prior organ allograft
- Pregnant or breastfeeding women
- Compulsory detention for psychiatric or physical illness treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
W
Weidong Han, doctor
CONTACT
Q
Qingming Yang, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here